“With the recent completion of the last patient visit in our Phase 3 EFZO-FIT(TM) study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, we are on track to report topline data in mid-September,” said Sanjay S. Shukla, President and Chief Executive Officer of aTyr. “This upcoming readout represents a major inflection point for aTyr, our clinical program for efzofitimod in ILD, and the broader sarcoidosis community, and we look forward to sharing the results.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma Inc put volume heavy and directionally bearish
- Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
- aTyr Pharma management to meet with Cantor Fitzgerald
- High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
- Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis